LAS VEGAS, May 09, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (“Item 9 Labs” or the “Company”), a leader in comfortable cannabis health solutions for the modern consumer, today announced its medical cannabis cultivation and processing facility Strive Wellness of Nevada will prioritize sustainable initiatives throughout construction.
Item 9 Labs broke ground on the project in April 2019 and will be producing legal medical cannabis products under organic practices by Q4. Located in Pahrump, Nevada, the 20,000 square-foot operation includes distribution rights.
“It is incredibly rewarding to see the Nevada cultivation and processing facility come to life,” stated CEO Sara Gullickson. “Ultimately, this license led me to forge my partnership with Item 9 Labs, which has evolved into a strong relationship of shared values and vision. Together, we are bringing best of industry practices to operations across the country.”
In November 2018, Item 9 Labs partnered with Bowden Investment Group to assist with environmentally friendly building strategies. The group is noted for constructing the first 100% sustainable apartment complex in Scottsdale, Arizona.
“With such a great and natural product under the roof, it only makes sense to combine a sustainable approach to the way we build and outfit the facility with the best materials and the latest, most efficient equipment for growing,” stated Andrew Bowden, CEO of Bowden Investment Group and Item 9 Labs board member.
Bowden Investment Group is currently enhancing Item 9 Labs’ Arizona cultivation and processing facility by introducing state-of-the-art custom environmental and irrigation controls, as well as an upgraded lighting system to increase efficiency and reduce energy use.
Item 9 Labs will be operating as licensed dispensaries, cultivation, and manufacturing facilities in a projected six to ten U.S. markets by the end of 2019.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer. The Company is bringing best of industry practices to markets from coast to coast through cultivation and production, distinctive retail environments, licensing services, and diverse product suites catering to different medical cannabis demographics. Item 9 Labs Corp. is headquartered in Phoenix, Arizona, with medical cannabis operations in multiple U.S. markets.
Item 9 Labs Corp.’s asset portfolio includes Dispensary Permits, Dispensary Templates, and Strive Life. These assets provide services specific to different stakeholder groups. Dispensary Permits is the Company’s consulting firm specializing in strategic license application and compliance. Dispensary Templates, a subdivision of the firm, is a technology platform with an extensive digital library of licensing and business planning resources. Strive Life is a turnkey dispensary model for the retail sector, elevating the patient experience with consistent and superior service, high-end design, and precision-tested products. It is currently being implemented in Arizona and North Dakota.
In addition, Item 9 Labs Corp. is advancing the industry with its dynamic product suites. The Company has created complementary brands Item 9 Labs and Strive Wellness to channel consumer diversity. Propriety delivery platforms include the Apollo Vape and Pod system, as well as a pioneering intra-nasal device. The Company has received multiple accolades for its medical-grade flower and concentrates.
Item 9 Labs Corp. will be managing cultivation, processing, distribution, and dispensary operations in up to ten U.S. markets by the end of 2019. Current facilities include distribution and processing operations Strive Wellness of Ohio and Strive Wellness of Nevada, as well as dispensary Strive Life North Dakota.
For more information, visit Item 9 Labs Corp. at www.Item9labscorp.com.
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact:
Neko Catanzaro
Proven Media
Neko@provenmediaservices.com
(401) 484-4980
Investor Contact:
Jeffrey Rassás
Item 9 Labs Corp.
Jeffrey@item9labs.com
(602) 463-4246